Clinical Trials

400 enrolled

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT07537972 2026-04-17

Denosumab Strategy for Liver Cancer With Bone Metastases

50 enrolled

Carcinoma, Hepatocellular

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

100 enrolled

Carcinoma, Hepatocellular

NCT07515625 2026-04-07

Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma

46 enrolled

Stomach Neoplasms

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

29 enrolled

Rectal Neoplasms

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular, Recurrence

NCT07067450 2025-07-16

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

98 enrolled

Esophageal Squamous Cell Carcinoma

NCT07018063 2025-06-12

YOUNG-NEOS

35 enrolled

Neoplasms, Stomach Neoplasms

NCT07007767 2025-06-06

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

32 enrolled

Phase 2/3 Not yet recruiting

Colorectal Cancer Metastatic

NCT06977061 2025-05-16

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Stomach Neoplasms

NCT06888648 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Pancreatic Cancer Metastatic

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

60 enrolled

Pancreatic Cancer Resectable

NCT06788171 2025-01-23

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

35 enrolled

Colorectal Cancer Liver Metastasis

NCT05562297 2025-01-22

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT06748508 2024-12-27

FDZL-GC003

141 enrolled

Stomach Neoplasms

NCT06697366 2024-11-20

Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer

27 enrolled

Stomach Neoplasms

NCT06652412 2024-10-28

CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC

124 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT06594692 2024-09-19

mRCAT-C

140 enrolled

Colonic Neoplasms, Spinocerebellar Degenerations

NCT06564298 2024-08-28

A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis

39 enrolled

Stomach Neoplasms

NCT06512467 2024-07-22

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT06499610 2024-07-12

Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT06454435 2024-06-12

Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

158 enrolled

Stomach Neoplasms

NCT06447636 2024-06-07

Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma

20 enrolled

Stomach Neoplasms

NCT06408623 2024-05-10

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

48 enrolled

Liver Neoplasms

NCT06089369 2024-04-30

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

360 enrolled

Carcinoma, Hepatocellular

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

220 enrolled

Colorectal Neoplasms

NCT06152978 2023-12-01

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

182 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06094868 2023-10-23

Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

45 enrolled

Stomach Neoplasms

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

104 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

668 enrolled

Carcinoma, Hepatocellular

NCT05244798 2022-10-25

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

420 enrolled

Esophageal Squamous Cell Carcinoma

NCT05507632 2022-08-19

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

48 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT05484024 2022-08-02

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

588 enrolled